Previous Close | 29.45 |
Open | 29.45 |
Bid | 26.62 x 200 |
Ask | 26.94 x 100 |
Day's Range | 26.50 - 29.79 |
52 Week Range | 8.79 - 42.20 |
Volume | |
Avg. Volume | 3,350,172 |
Market Cap | 1.291B |
Beta (5Y Monthly) | -0.62 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.83 |
Earnings Date | Nov 05, 2024 - Nov 11, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Dec 13, 2012 |
1y Target Est | 103.00 |
AUSTIN, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present at the H.C. Wainwright 26th Annual Global Investment Conference, being held in New York. Rick Barry, Cassava’s Executive Chairman, will join in a ‘fireside chat’ with Vernon T. Bernardino, PhD., Managing Director, Biotechnology Equity Research, at H.C. Wainwright. Institutional investors
We recently compiled a list of the 7 Best Debt Free Stocks To Buy. In this article, we are going to take a look at where Cassava Sciences Inc (NASDAQ:SAVA) stands against the other debt free stocks. Debt has always been the fuel driving many companies in the equity markets. Access to cheap capital when […]
With the business potentially at an important milestone, we thought we'd take a closer look at Cassava Sciences, Inc.'s...